Abstract:Introduction Gastric cancer (GC) is the fourth most common cancer and the third-leading cause of cancer-related deaths worldwide. Despite certain advances in chemotherapy regimens and targeted therapies, the 5 year survival of patients with advanced GC is disappointing. The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC) refractory to two or more lines of prior systemic chemotherapies. However, a dose reduction or treatment interruption is required to prevent apatinib toxicity such as hand-foot skin reaction (HFSR), proteinuria, and hypertension. In addition, suitable biomarkers are not accessible for identifying the patients who are most likely to benefit from apatinib. Therefore, predictive biomarkers are urgently needed to reduce toxicity and identify patients that will benefit from apatinib treatment. Material and methods Clonogenic assay, cytotoxicity assay, apoptosis assay, qRT-PCR, western blot were conducted in GC cells to evaluate the effectiveness of apatinib in vitro. Confocal microscopy assay was peformed to examine apatinib-induced autophagic flux in GC cells. Transmission electron microscopy assay was conducted to show the formation of autophagic vesicles. Xenograft models in mice were conducted and six tumour tissues were sent for miRNA-seq and circRNA-seq. Sanger sequencing was applied to determine the full length of the amplification products. Results and discussions In this study, we found that apatinib inhibited the growth of GC cells and xenograft tumours. Apatinib promoted autophagy activation via upregulation of ATG7 expression, and autophagy inhibition enhanced apatinib-induced apoptosis. With miRNA-seq and circRNA-seq analyses of GC xenograft models, we demonstrated that circRNA004582 functioned as an endogenous sponge for miR-3657 to inhibit its activity and further upregulate ATG7 expression. Silencing of circRNA004582 inhibited apatinib-induced autophagy, which was rescued by miR-3657. Moreover, knockdown of circRNA004582 promoted apatinib-induced apoptosis in GC cells. These findings provided the first evidence that the circRNA004582-miR-3657-ATG7 axis mediates a regulatory pathway critical for the regulation of autophagy and apatinib sensitivity in GC cells and xenografts. Conclusion In conclusion, specific blockage of circRNA004582 may be a potential therapeutic target for autophagy inhibition in the context of apatinib treatment in human GC. Prospective clinical studies are warranted to examine these biomarkers.

Regulation of Apelin Is Associated with Proliferation and Angiogenesis in Gastric Cancer

Apelin Over-Expression Promotes Proliferation and Angiogenesis of Gastric Cancer Cells

Role of REG Iα in Gastric Carcinogenesis: Gastrin-associated Proliferative and Anti-Apoptotic Activities.

Study Progression of Apelin/APJ Signaling and Apela in Different Types of Cancer

Apolipoprotein C1 regulates gastric cancer progression by inducing epithelial-mesenchymal transition via the JAK/STAT pathway

ANGPTL1 Attenuates Colorectal Cancer Metastasis by Up-Regulating Microrna-138

Apelin/APJ signaling activates autophagy to promote human lung adenocarcinoma cell migration

Apelin Enhances Biological Functions in Lung Cancer A549 Cells by Downregulating Exosomal Mir-15A-5p

Mining the Role of Angiopoietin‐like Protein Family in Gastric Cancer and Seeking Potential Therapeutic Targets by Integrative Bioinformatics Analysis

APLN Promotes the Proliferation, Migration, and Glycolysis of Cervical Cancer Through the PI3K/AKT/mTOR Pathway

Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway

Apelin13/APJ promotes proliferation of colon carcinoma by activating Notch3 signaling pathway.

Single‐cell and spatial transcriptomics reveal apelin/APJ pathway's role in microvessel formation and tumour progression in hepatocellular carcinoma

Inhibition of APLN Suppresses Cell Proliferation and Migration and Promotes Cell Apoptosis in Esophageal Cancer Cells in Vitro, Through Activating PI3K/mTOR Signaling Pathway.

Cancer apelin receptor suppresses vascular mimicry in malignant melanoma

Knockdown of Angiopoietin-Like 4 Inhibits the Development of Human Gastric Cancer.

Ghrelin Affects Gastric Cancer Progression by Activating AMPK Signaling Pathway

Autocrine VEGF Signaling Promotes Cell Proliferation Through a PLC-dependent Pathway and Modulates Apatinib Treatment Efficacy in Gastric Cancer.

GPAA1 Promotes Gastric Cancer Progression Via Upregulation of GPI-anchored Protein and Enhancement of ERBB Signalling Pathway

PO-071 Silencing of Circrna004582 Sensitises Gastric Cancer Cells to APATINIB Via Modulating Autophagy by Targeting Mir-3657 and ATG7

APPL1 Promotes the Migration of Gastric Cancer Cells by Regulating Akt2 Phosphorylation.